Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845844 | 0.80 | MAPT (0.55) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3739365 | 0.75 | PARP1 (0.53) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28669892 | 0.74 | NPC1 (0.63) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9965417 | 0.72 | EPHX2 (0.57) | MAPTKMT2ASMN1; SMN2EPHX2POLB | |
| SCHEMBL13041579 | 0.70 | PKM (0.44) | KMT2AMEN1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4104057 | 0.70 | EPHX2 (0.55) | MAPTSMN1; SMN2EPHX2POLBNPC1 | |
| SCHEMBL17187657 | 0.70 | EPHX2 (0.49) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13003435 | 0.70 | TSHR (0.65) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18138936 | 0.70 | POLB (0.51) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13041440 | 0.69 | EPHX2 (0.54) | MAPTKMT2ASMN1; SMN2EPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | MAPT 4781/4885KMT2A 4361/4885MEN1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.